Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day Mortality

The impact of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) global pandemic has been, and continues to be, significant [1]. Morbidity and mortality are considerable among older adults and those with comorbidities [2]. There has been an unprecedented global effort to develop strategies against SARS-CoV-2 infection, with ongoing trials assessing antiviral, anti-inflammatory, and immunomodulatory treatments to be used alongside public health measures [3]. Efforts to identify effective treatments to complement accelerating vaccination programs remain a public health priority [4].

Remdesivir is a direct-acting nucleotide-analog prodrug that inhibits \textit{Coronaviridae} ribonucleic acid (RNA)-dependent RNA polymerase through incorporation of its triphosphate form into the viral RNA [5]. Remdesivir inhibits SARS-CoV-2 replication in vitro [6, 7], and accumulating clinical evidence supports its use in patients with moderate or severe SARS-CoV-2 infection [8–12]. Data from a double-blind, randomized controlled trial indicated a reduced time to recovery in patients hospitalized with SARS-CoV-2 infection receiving intravenous remdesivir for 10 days compared with placebo (median time to recovery 10 days [95% confidence interval [CI], 9–11 days] vs 15 days [95% CI, 13–18 days]) [11]. Remdesivir was approved by the US Food and Drug Administration for use in hospitalized adults...
and pediatric patients (≥12 years and weighing ≥40 kg) with SARS-CoV-2 infection and received conditional marketing authorization from the European Medicines Agency for use in patients with SARS-CoV-2-related pneumonia receiving supplemental oxygen.

The efficacy of remdesivir in patients with severe SARS-CoV-2 infection was recently assessed in a comparative analysis of data from 2 studies: (1) a prospective phase 3, placebo-controlled, randomized study of remdesivir [8] and (2) a real-world retrospective cohort study of patients receiving standard-of-care therapy [13]. In an interim analysis, day 14 clinical recovery (based on improvement on a 7-point ordinal scale) was reported in 74.4% of patients in the remdesivir cohort compared with 59.0% in the nonremdesivir cohort (adjusted odds ratio [OR], 2.03; 95% CI, 1.34–3.08; \( P < .001 \)) [13]. The secondary endpoint of day 14 mortality was lower in the remdesivir cohort versus the nonremdesivir cohort (7.6% vs 12.5%; adjusted OR, 0.38; 95% CI, 0.22–0.68; \( P = .001 \)) [13]. In the final analysis, presented herein, after accrual of additional patients to allow for propensity matching, we describe the final results of this comparative study, the coprimary endpoints of day 14 clinical recovery, and day 28 all-cause mortality.

**METHODS**

The study design, patient populations, and endpoints from this comparative analysis have been described previously [13]. The prospective Study 5773 (Clinical trial: NCT04292899/GS-US-540-5773) is a phase 3, randomized, open-label study conducted at 55 sites in the United States, Europe, and Asia [8]. The retrospective Study 5807 (Clinical trial: EUPAS34303/GS-US-540-5807) was a real-world longitudinal cohort study conducted at 32 sites in the United States, Europe, and Asia.

**Patient Consent Statement**

In prospective Study 5773, the protocol was approved by local institutional review boards or independent ethics committees, and the study was conducted in accordance with the principles of the Declaration of Helsinki and International Conference on Harmonisation Good Clinical Practice guidelines. In Study 5773, patients or their legally authorized representative provided written informed consent or assent. Retrospective Study 5807 was conducted in compliance with Good Pharmacoepidemiology and Good Pharmacovigilance Practice. In Study 5807, patients or their legally authorized representative provided written informed consent or assent for the use of deidentified secondary data as appropriate and when required by the regulations of the individual Institutional Review Boards.

**Patients**

The inclusion criteria for patient enrollment in Study 5807 were designed to align with those in Study 5773 (described previously [8, 13]). Both studies enrolled patients with SARS-CoV-2 infection confirmed by polymerase chain reaction who had oxygen saturation ≤94% on room air or required supplemental oxygen and with radiographically confirmed pulmonary infiltrates (ie, patients with severe coronavirus disease 2019 [COVID-19]). Only patients aged ≥18 years were included in the current analysis.

To ensure comparability of patient populations, the exclusion criteria for prospective Study 5773 were retroactively applied to the retrospective Study 5807 population. Thus, patients were excluded from both studies if they had venoarterial extracorporeal membrane oxygenation on day 1; alanine transferase >5× upper limit of normal; creatinine clearance <50 mL/min (Cockcroft-Gault formula); or were pregnant or breastfeeding. Patients were excluded from prospective Study 5773 if they were receiving medication for the treatment of SARS-CoV-2 infection or mechanical ventilation at screening; however, patients enrolled in retrospective Study 5807 were allowed to receive treatments for SARS-CoV-2 infection, excluding remdesivir. Between the interim and final analyses, an additional 2074 patients were enrolled in retrospective Study 5807 (including patients in Spain/Italy, data from which were not available for the interim analysis) to allow for the propensity-matched analysis.

**Treatment**

In prospective Study 5773, patients were randomized 1:1 to receive open-label remdesivir 200 mg on day 1 followed by remdesivir 100 mg/day either on days 2–5 or on days 2–10 (randomization was 5 vs 10 days). All patients also received standard-of-care treatment (determined by local site practice). In the primary analysis of Study 5773, there was no significant difference in efficacy or safety outcomes according to remdesivir treatment duration, and therefore data from both treatment arms were pooled for this comparative analysis [8]. In retrospective Study 5807, all patients received standard-of-care treatment (nonremdesivir cohort) as determined by local treatment practices (except remdesivir, which was not approved for routine clinical use at the time of study).

**Endpoints**

The coprimary endpoints for retrospective Study 5807 final analysis were day 14 clinical recovery after initiation of treatment and day 28 all-cause mortality. Clinical status was determined using a 7-point ordinal scale as previously described [13] (Table 1).

An earlier preplanned interim analysis reported change in day 14 clinical status (recovery) in the remdesivir and nonremdesivir cohorts and day 14 mortality rates [13]. The present report documents the final analysis based on completed data collection from additional patients and full 28-day follow-up.
**Statistical Analysis**

Propensity score matching was used to form matched sets of patients from treated and control populations with similar propensity scores; no imputation was used in this analysis. Propensity scores were calculated using a logistic regression model to determine the probability of treatment assignment based on observed baseline characteristics as independent variables and treatment assignment (remdesivir vs no remdesivir) as the dependent variable. Baseline was defined as the start of remdesivir therapy in prospective Study 5773 and the date of hospitalization in retrospective Study 5807. Baseline factors included in the propensity score model are summarized in Table 2. See Supplementary Methods for further information on the propensity score matching. Recruitment for both studies was conducted before the results of the RECOVERY trial [14] and before the adoption of dexamethasone as part of standard of care in the clinic; thus, data on corticosteroid use were not collected in Study 5807.

For the primary analysis, recovery and mortality rates were analyzed using a generalized estimating equation (GEE) logistic regression model including treatment as an independent variable and matched sets as clusters [15]. Additional analyses evaluated factors associated with day 28 mortality using a multivariable GEE logistic regression model; covariates used in the model are listed in Table 2.

A subgroup analysis of patients categorized according to oxygen support status required at baseline (based on the 7-point ordinal scale) was conducted. The patient subgroups included those on invasive mechanical ventilation, high-flow oxygen (>6 L/min), low-flow oxygen (≤6 L/min), or room air (no supplemental oxygen required). SAS version 9.4 (SAS Institute Inc., Cary, NC) was used.

**RESULTS**

**Patients**

The first patient’s initial visit in Study 5773 was on March 6, 2020 and the last patient’s last visit was on April 27, 2020. The first patient enrolled in Study 5807 was hospitalized on February 6, 2020; data collection for Study 5807 was completed on May 15, 2020.

Of 397 patients who received remdesivir in Study 5773, 368 were included in the final analysis set (remdesivir cohort), whereas 1399 (from 2710 available before matching) were included from Study 5807 (nonremdesivir cohort) (Supplementary Figure 1).

After matching, a notable difference between remdesivir and nonremdesivir cohorts was the receipt of medications for COVID-19 treatment (Supplementary Table 1). Before baseline, azithromycin use was higher in the remdesivir than nonremdesivir cohort (32.3% vs 19.0%). After matching, the factors used for the propensity score matching were generally well balanced. Table 3 summarizes baseline demographics and disease characteristics in the matched populations. Both cohorts were broadly similar in terms of sex, age, race, and region of enrollment (Table 3). Comorbidities were also similar between treatment groups.

**Coprimary Analyses: Day 14 Clinical Recovery and Day 28 Mortality**

The day 14 clinical recovery rate was significantly higher in the remdesivir than nonremdesivir cohort (65.2% vs 57.1%; OR, 1.49; 95% CI, 1.16–1.90; \( P = .002 \)) (Figure 1A). Day 28 mortality was statistically significantly lower in the remdesivir than nonremdesivir cohort: 44 of 368 patients in the remdesivir cohort and 226 of 1399 in the nonremdesivir cohort had died (12.0% vs 16.2%; OR, 0.67; 95% CI, 0.47–0.95; \( P = .03 \)) (Figure 1B).

**Subgroup and Multivariable Mortality Analyses**

Day 14 recovery and day 28 mortality were evaluated after stratification for baseline oxygen requirement (Figure 2). The recovery rate was significantly higher for remdesivir-treated patients on low-flow oxygen at baseline compared with the nonremdesivir cohort on low-flow oxygen, 78.6% versus 65.7%, respectively (OR, 2.00; 95% CI, 1.38–2.90; \( P = .002 \)). The mortality rate was significantly lower for

| Ordinal Scale | Recovery Criteria |
|--------------|-------------------|
| 1            | Death             |
| 2            | Hospitalized and receiving invasive mechanical ventilation or ECMO |
| 3            | Hospitalized and receiving noninvasive ventilation or high-flow oxygen |
| 4            | Hospitalized and requiring low-flow supplemental oxygen |
| 5            | Hospitalized and not requiring supplemental oxygen but receiving ongoing medical care |
| 6            | Hospitalized and not requiring supplemental oxygen or ongoing medical care |
| 7            | Not hospitalized |

Abbreviations: ECMO, extracorporeal membrane oxygenation.

Table 1. Ordinal Scale and Recovery Criteria

*The ordinal scale was a modified version from that used by Cao et al [38] and that proposed in the draft WHO R&D Blueprint COVID-19 Therapeutic Trial Synopsis [37]. If an ongoing hospitalized patient had missing clinical status at a visit, then the last available post-baseline clinical status before the visit with the missing value was used for that visit.*
remdesivir-treated patients on low-flow oxygen at baseline compared with the nonremdesivir cohort on low-flow oxygen, 4.3% versus 12.5%, respectively (OR, 0.29; 95% CI, 0.14–0.58; \( P = .0005 \)). No significant differences in recovery or mortality were identified between both cohorts for patients who were on room air or high-flow oxygen. No recovery or mortality benefit was apparent for patients on mechanical ventilation at baseline, although the number of patients in this subgroup was small.

To evaluate additional factors influencing survival, a multivariable analysis that included remdesivir treatment and other factors associated with COVID-19 outcomes was performed. In the multivariable analysis, the OR for death by day 28, comparing the remdesivir versus nonremdesivir cohort, was similar to the primary analysis (OR, 0.65; 95% CI, 0.44–0.96; \( P = .03 \)) (Figure 3). This demonstrates that remdesivir treatment reduces mortality after accounting for all the factors included in the model. In addition (again, accounting for all the other factors in the model), a lower risk of death was associated with longer duration of symptoms before baseline, younger age, female sex, white race/ethnicity (vs black/African American), receiving a human immunodeficiency virus (HIV) protease inhibitor before or at baseline (where baseline was the start of remdesivir or date of hospitalization), not having cardiovascular disease or chronic obstructive pulmonary disease, and being on room air or low-flow oxygen at baseline (vs invasive mechanical ventilation).

**DISCUSSION**

Treatment with remdesivir was associated with a significant reduction in the rate of day 28 all-cause mortality compared with standard-of-care treatment in patients hospitalized with COVID-19. In addition, the day 14 clinical recovery rate was significantly higher in the remdesivir cohort. Because surges in SARS-CoV-2 infections have pushed healthcare systems to the limits of their capacity in some countries, a beneficial effect of remdesivir treatment in shortening clinical recovery times could ease the burden on hospitals.

These findings represent the final analysis of a previously reported interim analysis [13]. There are several important differences between the analyses. The present analysis used an increased population size in both the remdesivir and nonremdesivir groups, including >500 additional patients in the nonremdesivir cohort (818 in the interim/1399 in the final). The interim analysis used inverse probability of treatment weighting, because sample size in the nonremdesivir cohort was insufficient for matching (at time of analysis). The final analysis included sufficient nonremdesivir patients to enable propensity score matching. Propensity score matching was able to balance baseline covariates and ensure comparable populations regarding characteristics that might influence clinical outcome. In addition, patients from Italy and Spain were included in this analysis, further increasing global representation and generalizability (data unavailable for these patients at interim analysis). With the increased sample size and inclusion of additional patients from Europe, the day 28 mortality benefit and the day 14 clinical recovery benefit were confirmed (coprimary endpoints).

Several studies have evaluated remdesivir for COVID-19. In our study, we found a clear mortality benefit with remdesivir, but randomized trials have not demonstrated this. A randomized clinical trial conducted in China failed to identify a statistically significant difference in time to clinical improvement with remdesivir versus placebo in patients with severe COVID-19 (hazard ratio [HR], 1.23; 95% CI, 0.87–1.75) [12]. Day 28 mortality was also not different between arms in that study (HR, 1.1; 95% CI, −0.81 to 10.3). Notably, that study was underpowered due to poor enrollment and early study closure [16]. The ACTT-1 study compared remdesivir (200 mg loading dose followed by 100 mg daily for up to 9 additional days) with placebo in adults hospitalized with COVID-19 with evidence of lower respiratory tract infection [11]. Patients receiving remdesivir had a shorter time to recovery (defined as meeting the criteria for discharge).

### Table 2. Baseline Factors Included in the Propensity Score Model

| Baseline Factor                                                                 | Description                                                                 |
|---------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Duration of symptoms before baseline                                           |                                                                              |
| Clinical status using the 7-point ordinal scale score                           |                                                                              |
| Age (<40 years, 40–64 years, and ≥65 years)                                     |                                                                              |
| Sex                                                                              |                                                                              |
| Race (Asian, black, other, and white)                                          |                                                                              |
| Country of enrollment (Italy, Spain, United States, other)                      |                                                                              |
| Obesity                                                                         |                                                                              |
| Comorbidities (hypertension, cardiovascular disease, diabetes mellitus, COPD, asthma) |                                                                              |
| Investigational COVID-19 medications at the time of study design (azithromycin, biologics, HIV protease inhibitors, hydroxychloroquine, ribavirin) | taken at/before baseline                                                     |

Abbreviations: COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; HIV, human immunodeficiency virus.

*Baseline factors included in the propensity score model incorporated some of the sociodemographic factors and comorbidities outlined by the Centers for Disease Control and Prevention that may affect risk of severe illness [38].

Ribavirin was not included in the multivariable generalized estimating equation logistic regression model because the numbers were too low.
for the top 3 categories on an 8-point ordinal scale) compared with those receiving placebo (median time to recovery, 10 [95% CI, 9–11] vs 15 [95% CI, 13–18] days; rate ratio for recovery, 1.29 [95% CI, 1.12–1.49]; \( P < .001 \)) [11]. In addition, patients receiving remdesivir were more likely to have clinical improvement at day 15 than those receiving placebo (OR, 1.5, 95% CI, 1.2–1.9, after adjustment for disease severity). Consistent with the findings of the present analysis, Kaplan-Meier mortality estimates with remdesivir versus placebo were 6.7% versus 11.9% at day 15 (HR, 0.55; 95% CI, 0.36–0.83) and
11.4% versus 15.2% at day 29 (HR, 0.73; 95% CI, 0.52–1.03). The benefit of remdesivir was most apparent in patients receiving low-flow oxygen—consistent with the results of our subgroup analysis, which demonstrated a highly significant recovery and

**Figure 1.** Primary endpoint analyses: (A) odds ratio for day 14 clinical recovery; (B) odds ratio for day 28 all-cause mortality. *P* value, odds ratio, and 95% confidence interval (CI) were based on the generalized estimating equation logistic regression with propensity-matched sets considered as clusters. Numbers for the nonremdesivir cohort are based on weighted statistics.

**Figure 2.** Subgroup analysis of patients categorized according to oxygen support status required at baseline (based on propensity score matching) for (A) day 14 recovery and (B) day 28 all-cause mortality. *P* value, odds ratio, and 95% confidence interval (CI) were based on the generalized estimating equation logistic regression with matched sets considered as clusters. Numbers for the nonremdesivir cohort are based on weighted statistics.
mortality benefit of remdesivir for patients on low-flow oxygen at baseline, but no significant effect for patients who required high-flow oxygen or mechanical ventilation at baseline. The subgroup analysis suggests that initiating remdesivir early in the disease course (eg, for patients on low-flow oxygen) may provide the maximum benefit. Limited sample size precluded definitive analyses in other subgroups.

The Solidarity Therapeutics Trial, comparing remdesivir with local standard-of-care, also evaluated mortality and reported a log-rank death rate ratio of 0.95 (95% CI, 0.81–1.11; P = .50; 301 of 2743 remdesivir vs 303 of 2708 control) [17]. Baseline oxygen status, other than mechanical ventilation, was not described in the Solidarity study. The subgroup of patients not on mechanical ventilation showed a rate ratio for death of 0.86 (99% CI, 0.67–1.11), which was not significant but used an extremely conservative 99% CI. Commentators have suggested that Solidarity’s failure to detect a benefit with remdesivir may be due to variations across trial sites in standards of care, timing of treatment initiation, intensive care unit standards, and disease burden [18, 19].

The efficacy of remdesivir has also been evaluated for moderate COVID-19 [20]. Compared with standard care, patients receiving a 5-day course of remdesivir had a significantly higher odds of a better clinical status distribution on day 11 (OR, 1.65; 95% CI, 1.09–2.48; P = .02), whereas the clinical status distribution between the 10-day remdesivir and standard care groups was not significant (P = .18) [20], likely due to an interaction by open-label assignment resulting in a bimodal, rather than normal, distribution of date of hospital discharge. Real-world evidence supportive of remdesivir is also starting to accumulate, indicating that remdesivir could potentially have positive effects on clinical improvement and a favorable benefit/risk profile in different patient populations [9, 21, 22].

In light of the growing evidence base around pharmacological interventions, remdesivir is recommended for COVID-19 by the American Thoracic Society/European Respiratory Society Coordinated International Task Force [23], the National Institutes of Health [24], and the Infectious Diseases Society of America [25], as well as in several other national guidelines [3, 26–32]. However, the World Health Organization currently has a conditional recommendation against administering remdesivir in addition to usual care [33]. Further studies are required to identify the optimal combinations of pharmacological agents for treatment regimens including remdesivir.

The multivariable analyses in this study were built upon the growing body of evidence on the factors influencing the

**Figure 3.** Multivariable analysis of the odds ratio for day 28 all-cause mortality using generalized estimating equation logistic regression model. *Medications potentially active against coronavirus disease 2019. CI, confidence interval; COPD, chronic obstructive pulmonary disease.
survival of patients with severe COVID-19, with our model primarily aiming to investigate the robustness of the results of our primary analysis (ie, the treatment effect of remdesivir on mortality). The multivariable OR for treatment effect was comparable with the primary analysis, thereby confirming the treatment effect. In addition, the data suggested that after accounting for treatment arm, a lower risk of mortality was associated with the following: younger age, being female, being white (vs black/African American), being on low-flow oxygen or room air at baseline, receiving an HIV protease inhibitor before or at baseline, not having cardiovascular disease or chronic obstructive pulmonary disease, and (paradoxically) longer duration of symptoms before baseline. These results may differ from previous data in other publications [34–36] due to the nature of the cohorts and the analysis methods (including that our analysis was propensity matched). As noted, however, the model confirmed that remdesivir reduces mortality after accounting for all factors in the model (including duration of symptoms, ethnicity, and other medications).

Strengths and limitations of the present analysis are as previously described [13]. In brief, strengths include the following: the remdesivir data are derived from a large, phase 3 study and detailed patient-level data were available for the nonremdesivir cohort; propensity score matching maximized comparability across treatment groups; and both studies ran in parallel, ensuring consistent standard of care in both populations in the early days of the pandemic. In addition, the 28-day time point is reflective of the protracted course of the disease. Limitations include (1) the comparison of data from a prospective randomized study versus those from a retrospective, observational, nonrandomized treatment cohort, (2) that open-label treatment with remdesivir may be a source of bias (indeed, more patients in the nonremdesivir group received other medications with potential activity against COVID-19), (3) potential residual confounding even after application of propensity score matching, and (4) that the use of unproven treatments for COVID-19 with potentially limited benefit (and potential harm) might have been more widespread in the nonremdesivir cohort. Finally, although the benefits of systemic corticosteroid therapy among hospitalized patients with SARS-CoV-2 infection were demonstrated in the RECOVERY trial [14], our study was conducted before those results. Thus, we did not capture corticosteroid use in the nonremdesivir cohort and could not evaluate the combined impact of remdesivir with corticosteroids.

CONCLUSIONS

Remdesivir was associated with significantly higher rates of day 14 clinical recovery and lower day 28 mortality compared with standard-of-care treatment in hospitalized patients with COVID-19. These data support the use of remdesivir to improve clinical recovery and lower mortality from SARS-CoV-2 infection. In addition, by improving clinical recovery, remdesivir may help to reduce the burden on hospitals during surges in SARS-CoV-2 infections.

Supplementary Data

Supplementary materials are available at Open Forum Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Acknowledgments

We thank all patients and investigators involved in the study. Medical writing support was provided by Dr. Emma McConnell at Aspire Scientific Limited (Bollington, UK) and funded by Gilead Sciences. Gilead Sciences makes available anonymized individual patient data upon request or as required by law or regulation with external researchers. Approval of such requests is at Gilead Sciences’ discretion and is dependent on the nature of the request, the merit of the research proposed, the availability of the data, and the intended use of the data. Data requests should be sent to datarequest@gilead.com. Data from GS-US-540-5807 can only be provided with each participating institution’s prior written consent.

Data sharing statement

Gilead Sciences makes available anonymized individual patient data upon request or as required by law or regulation with external researchers. Approval of such requests is at Gilead Sciences’ discretion and is dependent on the nature of the request, the merit of the research proposed, the availability of the data, and the intended use of the data. Data requests should be sent to datarequest@gilead.com. Data from GS-US-540-5807 can only be provided with each participating institution’s prior written consent.

Author contributions. R. H. H., A. P. C., H. D.-C., I.-H. L., and H. H. designed the study. S. A. O., T. L. W., E. M., K. K. P., A. C., S. W., D. K. P. G., D. R., B. B., F. G. D. R., S. D. W., S.-W. K., G. D., R. B., K. M., D. C. L., R. L. G., J. I. B., and M. B. acquired the study data. All authors analyzed or interpreted the data. All authors were involved in drafting or critical revision of the manuscript and provided approval of the final manuscript for submission.

Financial support. This study was funded by Gilead Sciences, Inc.

Potential conflicts of interest. The study sponsor, Gilead Sciences, played a role in the study design, data collection and analysis, decision to publish, and preparation of the manuscript. S. A. O. and S. W. received research funding from Gilead Sciences. E. M. received honoraria for lectures or advisory boards; his institution has received research grants from Gilead, Janssen, MSD, and Viiv. K. K. P. received nonfinancial support from Gilead Sciences. A. C. received research funding from Gilead Sciences, Viiv, MSD, and Janssen. D. R. acted as a consultant for Bristol Myers Squibb. P. G. received personal fees for medicolegal consulting on heart failure and has received honoraria from Akcea and Bionest. D. R. received honoraria for lectures or advisory boards from Gilead Sciences, Janssen, and Viiv. B. B. received honoraria for lectures from Gilead Sciences. F. G. D. R. received speaker fees from Gilead, unrelated to the current work. S. D. W. received honoraria for advisory boards; his institution received research grants from Gilead Sciences, Janssen, MSD, and Viiv. G. D. serves as a consultant for Lexicon Pharmaceuticals, Scientific Advisory Board for Safeology, Inc., and provides expertise for the Gilead Medical Affairs Sentinel Panel; his institution has received research grants from Gilead Sciences, Regeneron, Boehringer Ingelheim, and Roche. R. B. received honoraria for lectures/advisory boards for Abbott, Gilead Sciences, MSD, and Roche. K. M. received a grant for funding of the 5773/5774 remdesivir clinical trials and was a consultant for Gilead Sciences. D. C. L. is on the COVID-19 global advisory panel (no personal honorarium) for Gilead Sciences. R. L. G. reports nominal consulting for Gilead Sciences; and Gift-in-kind (nonfinancial support) to Baylor Scott & White Research Institute to support ClinicalTrials.
References
1. Johns Hopkins University and Medicine. Coronavirus resource center. Available at: https://coronavirus.jhu.edu/. Accessed 17 February 2021.
2. Richardson S, Hirsch JS, Narasimhan M, et al; the Northwell COVID-19 Research Consortium. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 2020; 323:2052–9.
3. Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA 2020; 324:782–93.
4. Kane PB, Moyer H, MacPherson A, et al. Expert forecasts of COVID-19 vaccine development timelines. J Gen Intern Med 2020; 35:3753–5.
5. Gordon CJ, Tchesnokov EP, Woolner E, et al. Remdesivir is a direct-acting anti-viral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem 2020; 295:6785–97.
6. Prijssers AJ, George AS, Schafer A, et al. Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice. Cell Rep 2020; 32:107940.
7. Bravo JPK, Dangerfield TL, Taylor DW, Johnson KA. Remdesivir is a delayed translocation inhibitor of SARS-CoV-2 replication. Mol Cell 2021; 81:1548–52. e4.
8. Goldman JD, Lye DCR, Hui DS, et al.; GS-US-540-5773 Investigators. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med 2020; 383:1827–37.
9. Antinori S, Cosso MV, Rialollo AL, et al. Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: clinical outcome and differences in post-treatment hospitalisation status. Pharmacol Rep 2020; 158:104899.
10. Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med 2020; 383:1813–26.
11. Beigel JH, Tomashek KM, Dodd LE, et al.; ACTT-1 Study Group Members. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med 2020; 383:1813–26.
12. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020; 395:1569–78.
13. Olender SA, Perez KK, Go AS, et al. Remdesivir for severe COVID-19 versus a cohort receiving standard of care. Clin Infect Dis 2020. doi: 10.1093/cid/ciaa1041.
14. The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 2021; 384:693–704.
15. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986; 73:13–22.
16. Norrie JD. Remdesivir for COVID-19: challenges of underpowered studies. Lancet 2020; 395:1525–7.
17. WHO Solidarity Trial Consortium. Repurposed antiviral drugs for Covid-19 — interim WHO Solidarity trial results. N Engl J Med 2021; 384:497–511.
18. Hashemian SMR, Jamaati H, Norizadatehazekand M, et al. Dubious results of remdesivir ultimately in solidarity; diversity of severity illness is doubtful. New Emirates Med J 2020; 1:1.
19. Harrington DP, Baden LR, Hogan JW. A large, simple trial leading to complex questions. N Engl J Med 2021; 384:576–7.
20. Spinner CD, Gottlieb RL, Criner GI, et al.; GS-US-540-5774 Investigators. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA 2020; 324:1048–57.
21. Petit NN, Pisano J, Nguyen CT, et al. Remdesivir use in the setting of severe renal impairment: a theoretical concern or real risk? Clin Infect Dis 2020. doi: 10.1093/cid/ciaa1851.
22. Flišář R, Zarebska-Michaluk D, Berkan-Kawinska A, et al. Remdesivir-based therapy improved recovery of patients with COVID-19 in the SARTer multicentre, real-world study. Pol Arch Intern Med 2021; 131:103–10.
23. Bai C, Chotirmall SH, Rello J, et al. Updated guidance on the management of COVID-19 from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020). Eur Respir Rev 2020; 29:200287.
24. National Institutes of Health. Therapeutic management of patients with COVID-19. Available at: https://www.covidtreatmentguidelines.nih.gov/therapeutic-management/. Accessed 17 February 2021.
25. Infectious Diseases Society of America. Guidelines on the treatment and management of patients with COVID-19. Available at: https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/#toc-8. Accessed 17 February 2021.
26. Kluge S, Janssens U, Welte T, et al. Recommendations for treatment of critically ill patients with COVID-19: version 3.51 guideline. Anaesthesist 2020. doi: 10.1007/s00101-020-00879-3.
27. Canadian Critical Care Society and Association of Medical Microbiology and Infectious Disease (AMMI) Canada. Clinical management of patients with COVID-19: second interim guidance. Available at: https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/clinical-management-covid-19.html. Accessed 17 February 2021.
28. Pakistan Chest Society; COVID-19 management guidelines. 2020. Available at: http://www.pakistanchestsociety.pk/wp-content/uploads/2020/03/COVID-19-Management-guideline-PCS-28-March.pdf. Accessed 17 February 2021.
29. Nicastri E, Petrosillo N, Ascoli Bartoli T, et al. National Institute for the Infectious Diseases "L. Spallanzani"; IRCCS. Recommendations for COVID-19 clinical management. Infect Dis Rep 2020; 12:8543.
30. Kurtasç Aytırm K, Köseoğlu BF, Özyemişçi Taşkıran Ö, et al. Pulmonary rehabilitation principles in SARS-COV-2 infection (COVID-19): a guideline for the acute and subacute rehabilitation. Turk J Phys Med Rehabil 2021; 66:104–20.
31. Japan Ministry of Health Labour and Welfare, National Institute of Infectious Diseases. COVID-19 guidelines. Available at: https://www.mhlw.go.jp/content/000668291.pdf. Accessed 17 February 2021.
32. Deutsche Gesellschaft für Infektologie. Update of the consensus recommendations on COVID-19 pharmacotherapy of the German Society for Infectious Diseases (DGI). Available at: https://www.dgi-net.de/update-der-konsensus-empfehlungen-zur-covid-19-pharmakotherapie-der-deutschen-gesellschaft-fuer-infektiologie-dgi/. Accessed 17 February 2021.
33. World Health Organization. Therapeutics and COVID-19: living guideline. Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2021.1. Accessed 29 April 2021.
34. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395:1054–62.
35. Ogedegbe G, Raveln J, Adhikari S, et al. Assessment of racial/ethnic disparities in hospitalization and mortality in patients with COVID-19 in New York City. JAMA Netw Open 2020; 3:e2026881.
36. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020; 382:1787–99.
37. World Health Organization. WHO R&D blueprint: novel coronavirus. COVID-19 therapeutic trial synopsis. Available at: https://www.who.int/blueprint/priority-diseases/key-action/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf. Accessed 17 February 2021.
38. Centers for Disease Control and Prevention. COVID-19: people at increased risk and other people who need to take extra precautions. Available at: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/index.html. Accessed 17 February 2021.